Literature DB >> 23980917

Computed tomography predictors of hepatocellular carcinoma tumour necrosis after chemoembolization.

Mary K Bryant1, David P Dorn, Jessica Zarzour, J Kevin Smith, David T Redden, Souheil Saddekni, Ahmed Kamel Abdel Aal, Stephen H Gray, Devin E Eckhoff, Derek A Dubay.   

Abstract

BACKGROUND: Radiographical features associated with a favourable response to trans-arterial chemoembolization (TACE) are poorly defined for patients with hepatocellular carcinoma (HCC).
METHODS: From 2008 to 2012, all first TACE interventions for HCC performed at the University of Alabama at Birmingham (UAB) were retrospectively reviewed. Only patients with a pre-TACE and a post-TACE computed tomography (CT) scan were included in the analyses (n = 115). HCC tumour response to TACE was quantified via the the modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria. Univariate and multivariable analyses were constructed.
RESULTS: The index HCC tumours experienced a > 90% or complete tumour necrosis in 59/115 (51%) of patients after the first TACE intervention. On univariate analysis, smaller tumour size, peripheral tumour location and arterial enhancement were associated with a > 90% or complete tumour necrosis, whereas, only smaller tumour size [odds ratio (OR) 0.62; 95% confidence interval (CI) 0.48, 0.81] and peripheral location (OR 6.91; 95% CI 1.75, 27.29) were significant on multivariable analysis. There was a trend towards improved survival in the patients that experienced a > 90% or complete tumour necrosis (P = 0.08).
CONCLUSIONS: Peripherally located smaller HCC tumours are most likely to experience a > 90% or complete tumour necrosis after TACE. Surprisingly, arterial-phase enhancement and portal venous-phase washout were not significantly predictive of TACE-induced tumour necrosis. The TACE response was not statistically associated with improved survival.
© 2013 International Hepato-Pancreato-Biliary Association.

Entities:  

Mesh:

Year:  2013        PMID: 23980917      PMCID: PMC3967884          DOI: 10.1111/hpb.12149

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  21 in total

1.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.

Authors:  J Bruix; M Sherman; J M Llovet; M Beaugrand; R Lencioni; A K Burroughs; E Christensen; L Pagliaro; M Colombo; J Rodés
Journal:  J Hepatol       Date:  2001-09       Impact factor: 25.083

Review 2.  Evidence-based medicine in the treatment of hepatocellular carcinoma.

Authors:  Josep M Llovet
Journal:  J Gastroenterol Hepatol       Date:  2002-12       Impact factor: 4.029

3.  Transcatheter arterial chemoembolization confers survival benefit in patients with a spontaneously ruptured hepatocellular carcinoma.

Authors:  Jong Yeon Kim; June Sung Lee; Dong-Hoon Oh; Yun Hyuk Yim; Hyo Keun Lee
Journal:  Eur J Gastroenterol Hepatol       Date:  2012-06       Impact factor: 2.566

4.  Portal vein thrombosis and arterioportal shunts: effects on tumor response after chemoembolization of hepatocellular carcinoma.

Authors:  Thomas J Vogl; Nour-Eldin Nour-Eldin; Sally Emad-Eldin; Nagy Nn Naguib; Joerg Trojan; Hans Ackermann; Omar Abdelaziz
Journal:  World J Gastroenterol       Date:  2011-03-14       Impact factor: 5.742

5.  Semiautomated segmentation for volumetric analysis of intratumoral ethiodol uptake and subsequent tumor necrosis after chemoembolization.

Authors:  Wayne L Monsky; Isaac Kim; Shaun Loh; Chin-Shang Li; Tamara A Greasby; Larry-Stuart Deutsch; Ramsey D Badawi
Journal:  AJR Am J Roentgenol       Date:  2010-11       Impact factor: 3.959

6.  Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.

Authors:  Josep M Llovet; Maria Isabel Real; Xavier Montaña; Ramon Planas; Susana Coll; John Aponte; Carmen Ayuso; Margarita Sala; Jordi Muchart; Ricard Solà; Joan Rodés; Jordi Bruix
Journal:  Lancet       Date:  2002-05-18       Impact factor: 79.321

7.  Underutilization of therapy for hepatocellular carcinoma in the medicare population.

Authors:  Shimul A Shah; Jillian K Smith; Youfu Li; Sing Chau Ng; James E Carroll; Jennifer F Tseng
Journal:  Cancer       Date:  2010-10-13       Impact factor: 6.860

8.  Analysis of survival predictors in a prospective cohort of patients undergoing transarterial chemoembolization for hepatocellular carcinoma in a single Canadian centre.

Authors:  Karim M Eltawil; Robert Berry; Mohamed Abdolell; Michele Molinari
Journal:  HPB (Oxford)       Date:  2012-01-09       Impact factor: 3.647

Review 9.  Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival.

Authors:  Josep M Llovet; Jordi Bruix
Journal:  Hepatology       Date:  2003-02       Impact factor: 17.425

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  8 in total

1.  Predictors of repeat transarterial chemoembolization in the treatment of hepatocellular carcinoma.

Authors:  Jared A White; David T Redden; Mary Kate Bryant; David Dorn; Souheil Saddekni; Ahmed Kamel Abdel Aal; Jessica Zarzour; David Bolus; J Kevin Smith; Stephen Gray; Devin E Eckhoff; Derek A DuBay
Journal:  HPB (Oxford)       Date:  2014-08-26       Impact factor: 3.647

2.  Sequential transarterial chemoembolization and portal vein embolization before resection is a valid oncological strategy for unilobar hepatocellular carcinoma regardless of the tumor burden.

Authors:  Maxime Ronot; François Cauchy; Bettina Gregoli; Romain Breguet; Wassim Allaham; Valérie Paradis; Olivier Soubrane; Valérie Vilgrain
Journal:  HPB (Oxford)       Date:  2016-06-18       Impact factor: 3.647

3.  Adjuvant stereotactic body radiotherapy following transarterial chemoembolization in patients with non-resectable hepatocellular carcinoma tumours of ≥ 3 cm.

Authors:  Rojymon Jacob; Falynn Turley; David T Redden; Souheil Saddekni; Ahmed K A Aal; Kimberly Keene; Eddy Yang; Jessica Zarzour; David Bolus; J Kevin Smith; Stephen Gray; Jared White; Devin E Eckhoff; Derek A DuBay
Journal:  HPB (Oxford)       Date:  2014-09-04       Impact factor: 3.647

Review 4.  Assessment of response to therapy in hepatocellular carcinoma.

Authors:  Tushar Patel; Denise Harnois
Journal:  Ann Med       Date:  2014-04-10       Impact factor: 4.709

5.  Predictive factors for complete response of chemoembolization with drug-eluting beads (DEB-TACE) for hepatocellular carcinoma.

Authors:  Guillaume Vesselle; Camille Quirier-Leleu; Stéphane Velasco; Florian Charier; Christine Silvain; Samy Boucebci; Pierre Ingrand; Jean-Pierre Tasu
Journal:  Eur Radiol       Date:  2015-10-11       Impact factor: 5.315

6.  Comprehensive Analysis of Factors Affecting Clinical Response and Short-Term Survival to Drug-Eluting Bead Transarterial Chemoembolization for Treatment in Patients With Liver Cancer.

Authors:  Xia Wu; Ran Chen; Weiliang Zheng; Hongjie Hu
Journal:  Technol Cancer Res Treat       Date:  2018-01-01

7.  Study of predictive factors of complete response after chemoembolization for unresectable hepatocellular carcinoma in 162 patients.

Authors:  El Hassani Younes; Hamdoun Fatima Zahra; Ben Maamar Soumaya; Lahlali Maria; Lahmidani Nada; Abid Hakima; El Fakir Samira; Haloua Meriem; Alami Badreddine; Hafidi Youssef; Kamaoui Imane; Boubbou Meryem; Aqodad Noureddine; Ibrahimi Sidi Adil; Maaroufi Mustapha; Alaoui Lamrani Moulay Youssef
Journal:  Clin Exp Hepatol       Date:  2020-12-30

8.  Simultaneous transcatheter arterial chemoembolization and portal vein embolization for patients with large hepatocellular carcinoma before major hepatectomy.

Authors:  Cheng-Wu Zhang; Chang-Wei Dou; Xin-Long Zhang; Xi-Qiang Liu; Dong-Shen Huang; Zhi-Ming Hu; Jie Liu
Journal:  World J Gastroenterol       Date:  2020-08-14       Impact factor: 5.742

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.